Printer Friendly

IMMUNOMEDICS PURSUES NEW CANCER THERAPY; PATENT ALLOWED FOR METHOD COMBINING CYTOKINES AND RADIOACTIVE ANTIBODIES

 IMMUNOMEDICS PURSUES NEW CANCER THERAPY; PATENT ALLOWED FOR
 METHOD COMBINING CYTOKINES AND RADIOACTIVE ANTIBODIES
 WARREN, N.J., Jan. 8 /PRNewswire/ -- Immunomedics, Inc. (NASDAQ: IMMU), announced today that the U.S. Patent Office has allowed a patent application for the company's new method of cancer treatment combining radioactive cancer-seeking monoclonal antibodies with certain cytokines, particularly blood cell growth factors. Several companies are developing or already marketing growth factors, such as G-CSF and GM-CSF, which are given in combination with cytotoxic drugs to stimulate white blood cells, offsetting the adverse effects of the chemotherapy.
 "A major limitation in cytotoxic cancer therapy is the toxicity to blood-forming cells of the bone marrow," noted Hans J. Hansen, vice president, exploratory research. "In order to enhance the therapeutic dose and effects of radiolabeled antibodies, certain cytokines or growth factors, including IL-1, IL-3, G-CSF, and GM-CSF, may be given with the cytotoxic radioantibodies, thus stimulating bone marrow cells," explained Hansen.
 Immunomedics is currently in clinical trials with two cancer therapeutics, one for colorectal cancer and another for lymphoma, consisting of radioactive antibodies that deliver the cytotoxic radioactivity to the cancers. "Upon the commencement of clinical trials, the company hopes to show that the combination of these agents with marrow-protective cytokines may spare bone marrow toxicity," commented Carl M. Pinsky, vice president, medical affairs.
 Russell C. McLauchlan, president, said, "Immunomedics already has a comprehensive patent portfolio covering radiolabeled antibodies for cancer imaging and therapy. With this new patent, we are expanding our proprietary technology."
 Immunomedics is a biopharmaceutical company applying innovative technology in antibody selection, modification and chemistry to the development of products for the detection and treatment of cancers and infectious diseases. Integral to these products are highly specific monoclonal antibodies designed to deliver radioisotopes, chemotherapeutic agents or toxins to tumors and sites of infections or other diseases.
 -0- 1/8/92
 /CONTACT: Amy Factor of Immunomedics, 908-647-5400/
 (IMMU) CO: Immunomedics, Inc. ST: New Jersey IN: MTC SU:


GK-OS -- NY066 -- 7659 01/08/92 09:57 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 8, 1992
Words:331
Previous Article:GENERAL RENT-A-CAR OFFERS LOWEST RATES IN FLORIDA
Next Article:AMERICAN MEDICAL ASSOCIATION AND CAMPBELL SOUP COMPANY TO OFFER HEALTHY EATING VIDEO
Topics:


Related Articles
IMMUNOMEDICS WINS U.S. PATENT OFFICE APPEAL; BROAD U.S. PATENT ON ORGAN IMAGING ALLOWED
IMMUNOMEDICS AWARDED PATENT FOR IMAGING AND THERAPEUTIC AGENTS
IMMUNOMEDICS ALLOWED PATENT FOR NEW CANCER IMAGING & THERAPY METHODS & AGENTS: FEDERAL GRANT FOR CANCER THERAPEUTIC ALSO AWARDED
IMMUNOMEDICS FILES FOR PRODUCT MARKETING APPROVAL IN CANADA; PRODUCT CONSISTS OF ADVANCED CANCER DETECTION METHOD
IMMUNOMEDICS RECEIVES BROAD EUROPEAN PATENT FOR HIGHLY SPECIFIC CANCER TARGETING ANTIBODIES
IMMUNOMEDICS REPORTS INITIAL CLINICAL RESULTS OF A NEW CANCER THERAPEUTIC; ANTIBODY HUMANIZATION PROGRAM ALSO ADVANCES
IMMUNOMEDICS REPORTS ON LYMPHOMA IMAGING AND THERAPY PROGRESS AT CANCER CONFERENCE
IMMUNOMEDICS GRANTED THREE PATENTS IN JAPAN
Immunomedics Awarded U.S. Patent for Therapeutic Conjugates of Toxins and Drugs
Immunomedics Wins Patent in Japan

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters